Catalyst Pharmaceuticals Inc SEC Filings

Catalyst Pharmaceuticals, Inc. disclosed that its Board of Directors has approved a share repurchase program authorizing the company to buy back up to $200 million of its common stock. The program runs from October 1, 2025 through December 31, 2026.

The company may repurchase shares through methods such as open market purchases or privately negotiated transactions. The timing and amount of any repurchases will depend on factors including stock price, business and market conditions, regulatory requirements, and alternative investment or acquisition opportunities. Catalyst plans to use existing cash on hand to fund the program, is not obligated to repurchase any specific amount, and may suspend or terminate the program at any time.

Brian Elsbernd, Chief Compliance/Legal Officer and Director of Catalyst Pharmaceuticals, reported option exercises and an open-market sale on 09/08/2025. He exercised 112,475 options at an exercise price of $2.24 per share, resulting in the acquisition of 112,475 common shares. To fund the exercise price and tax withholding, 30,000 shares were sold on the open market at a weighted average price of $20.30 (sales ranged from $20.225 to $20.315). Following these transactions, Mr. Elsbernd beneficially owned 271,039 shares directly and reported 846,609 derivative securities (options) beneficially owned. The options reported vested in three annual tranches beginning December 19, 2019.

Catalyst Pharmaceuticals (CPRX) filing a Form 144 notifies of a proposed sale of 30,000 common shares to be executed through Fidelity Brokerage Services on 09/08/2025 with an aggregate market value of $609,035.49 based on the filing. The shares were acquired through options granted 12/19/2018 and the reported payment method for the sale is cash. The filing also reports recent open-market disposals by the same person: 20,000 shares sold on 09/03/2025 for $401,514.00 and 30,000 shares sold on 09/04/2025 for $585,642.00. The filer attests no undisclosed material adverse information.

Catalyst Pharmaceuticals insider Brian Elsbernd, listed as the company's Chief Compliance/Legal Officer, reported option exercises and open-market sales on 09/03/2025 and 09/04/2025. He exercised 20,000 options on 09/03/2025 at a $2.24 exercise price and sold 20,000 common shares that day for a weighted average of $20.08 per share. On 09/04/2025 he exercised another 30,000 options at $2.24 and sold 30,000 shares for a weighted average of $19.52 per share. Following these transactions his beneficial ownership in common stock is reported as 188,564 shares and the filing shows remaining option positions underlying 989,084 and 959,084 shares after each exercise event as reported in Table II. The filing states the sales were on the open market for personal reasons and not due to any disagreement with the company.

Catalyst Pharmaceutical, Inc. (CPRX) filing a Form 144 notifies the proposed sale of 30,000 common shares through Fidelity Brokerage Services with an aggregate market value of $585,640.54. The shares represent options granted on 12/19/2018 and were acquired on 09/04/2025; payment is expected in cash. The filing lists 122,391,010 shares outstanding and names NASDAQ as the exchange for an approximate sale date of 09/04/2025. It also discloses a recent sale of 20,000 shares by Brian Elsbernd on 09/03/2025 for gross proceeds of $401,514.00. The filer certifies no undisclosed material adverse information.

Catalyst Pharmaceuticals (CPRX) reports a proposed Rule 144 sale of 20,000 common shares, to be transacted through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $401,514.10. The shares were acquired on 09/03/2025 via exercise of options originally granted on 12/19/2018, and payment for those shares is noted as cash. The filing indicates 122,391,010 shares outstanding for the issuer and states there were no securities sold by the reporting person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Insider transaction summary: Director David S. Tierney exercised stock options to acquire 50,000 shares of Catalyst Pharmaceuticals, Inc. common stock at an exercise price of $2.24 per share on 08/27/2025, resulting in 158,274 stock options/underlying derivative securities held following the transaction. To fund the exercise price and estimated taxes, Mr. Tierney sold 26,000 shares in the open market on the same date at a weighted average price of $20.20 per share (sales ranged from $20.10 to $20.32). After these transactions, Mr. Tierney beneficially owned 379,620 shares of common stock. The Form 4 was signed 08/28/2025.

Steve Miller, Chief Operating & Scientific Officer of Catalyst Pharmaceuticals (CPRX), reported option exercises and an open-market sale. On 08/26/2025 he exercised 115,000 options at an exercise price of $2.24 and sold 115,000 shares at a weighted average price of $20.28 (sales ranged $20.04–$20.645) to fund the exercise price and estimated taxes. After those transactions his reported beneficial ownership moved between 1,064,663 and 949,663 shares. On 08/27/2025 he exercised an additional 110,000 options at $2.24. The Form 4 was signed 08/28/2025.

Richard J. Daly, President and CEO and director of Catalyst Pharmaceuticals, reported exercises and a related sale on August 26, 2025. He exercised 50,000 stock options at an exercise price of $2.24 per share, and concurrently sold 22,970 common shares at $20.62 per share to fund the exercise price and tax withholding. Following these transactions, Mr. Daly reported 226,794 shares beneficially owned directly and reported derivative holdings that underlie 50,000 option shares; the filing lists total derivative-related beneficial ownership of 2,184,753 shares.